HXE

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcStudies on the Stability and Microbial Biotransformation of Five Deschloroketamine Derivatives as Prerequisite for Wastewater-Based Epidemiology Screening
3. 2026-09-07src1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
4. 2026-09-07srcKetamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn
5. 2026-09-07srcSalting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples
6. 2026-09-07srcBifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment
7. 2026-09-07srcDetailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat
8. 2026-09-07srcEmerging new psychoactive ketamine analogues: patterns of use and health risks identified by the French Addictovigilance Network
9. 2026-09-07srcNew insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat
10. 2026-09-07srcKetamine-snorting associated cystitis
11. 2026-09-07srcDerivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors
12. 2026-09-07srcMethoxetamine: A foe or friend?
13. 2026-09-07srcIn vitro and in vivo metabolic study of three new psychoactive β-keto-arylcyclohexylamines
14. 2026-09-07srcAnalytical findings of an acute intoxication after inhalation of methoxetamine
15. 2026-09-07srcFatal intoxication with methoxetamine
16. 2026-09-07srcKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
17. 2026-09-07srcMethoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order)
18. 2026-09-07srcKetamine-associated urinary tract dysfunction: an underrecognized clinical entity
19. 2026-09-07srcRedefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions
20. 2026-09-07srcThe ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
21. 2026-09-07srcAcute methoxetamine and amphetamine poisoning with fatal outcome: a case report
22. 2026-09-07srcMethoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation
23. 2026-09-07srcCharacterization of 3-Hydroxyeticyclidine (3-HO-PCE) Metabolism in Human Liver Microsomes and Biological Samples Using High-Resolution Mass Spectrometry
24. 2026-09-07srcEvaluation of urinary bladder fibrogenesis in a mouse model of long-term ketamine injection
25. 2026-09-07srcBilateral hydronephrosis and cystitis resulting from chronic ketamine abuse
26. 2026-09-07srcKetamine dependence
27. 2026-09-07srcHydroxetamine (HXE) Toxicology Report
28. 2026-09-07srcGovernment bans methoxetamine (mexxy) — GOV.UK with ACMD generic arylcyclohexylamine catch-all recommendation
29. 2026-09-07srcSchedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I
30. 2026-09-04issueIssued emergency
31. 2026-09-04issueIssued info_card
32. 2026-09-04issueIssued notice
33. 2026-06-04proposal54 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
34. 2026-06-04publicationPublication — backfill
35. 2026-05-07revisionRevision 1
36. 2026-05-07genGeneration — pipeline-v5 · with 3 morepipeline-v5
37. 2026-05-07rungeneration run

The same entries, as forms: six forms.